Skip to content

Molecular Biology Reports

ISSN 1573-4978

4 papers in the library · 3 citations · publishing 2020-2026

Papers

Sort Most recent Most cited

Targeting NMDAR2A in microglia: esketamine suppresses M1 polarization in BV2 cells.

Molecular Biology Reports October 22, 2026 Hui Li, Xiaoyuan Zhang, Yushan Luo et al.

Objective: Microglial polarization toward the M1 phenotype is a key contributor to the initiation and progression of neuroinflammatory diseases, primarily through the release of pro-inflammatory cytokines that exacerbate central nervous system-associated injury. Activation of N-methyl-D-aspartic acid receptors (NMDARs) is implicated in microglial overactivation and cytotoxicity. This study...

Effects of cerebrolysin on behavioral changes and the tryptophan-kynurenine pathway in the prefrontal cortex of male mice in the ketamine model of schizophrenia.

Molecular Biology Reports July 16, 2025 Vida Mafikandi, Leila Hosseini, Fatemehsadat Seyedaghamiri et al.

Cerebrolysin (CBL), a peptide derived from pig brain, is recognized for its neuroprotective and anti-inflammatory properties. This research aimed to investigate the effects of CBL on anxiety- and depression-like behaviors, spatial memory, the tryptophan/kynurenine (TRP/KYN) pathway, and inflammation in the prefrontal cortex (PFC) of a mouse model for schizophrenia. Thirty-six male BALB/c mice...

DOI: 10.1007/s11033-025-10820-9 (opens in new tab) Full text (opens in new tab) Cognitive dysfunction Cerebrolysin: cerebrolysin Schizophrenia research: schizophrenia Model mimicking schizophrenia +7

MDMA targets miR-124/MEKK3 via MALAT1 to promote Parkinson’s disease progression

Molecular Biology Reports September 9, 2023 Xin Geng, Shipeng Li, Jinghui Li et al. 3 citations

BACKGROUND: Parkinson's disease (PD) is a well-known neurodegenerative disease that is usually caused by the progressive loss of dopamine neurons and the formation of Lewy vesicles. 3,4-Methylenedioxymethamphetamine (MDMA) has been reported to cause damage to human substantia nigra neurons and an increased risk of PD, but the exact molecular mechanisms need further investigation. METHODS: MPTP-...

Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review

Molecular Biology Reports December 1, 2020 Alec J. DiVito, Robert F. Leger

Classical psychedelics are a group of drugs characterized by their activation of the serotonin-2A (5-hydroxytryptamine-2A; 5-HT2A) receptor and the unique hallucinogenic and mystical-type experiences that result. After a substantial period of restrictions limiting investigations into the therapeutic potential of psychedelics, a relatively recent recommencement of interest has sparked the...

DOI: 10.1007/s11033-020-06009-x (opens in new tab) Full text (opens in new tab) Addiction Smoking cessation Psychedelics Serotonergic hallucinogen